argenex SE (NASDAQ:ARGX) Receives $817.53 Average Target Price from Analysts

argenex SE (NASDAQ:ARGX) has received an average recommendation of “Buy” from the twenty-four ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, twenty have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $817.5263.

Several analysts recently issued reports on the company. Morgan Stanley upped their target price on argenex from $766.00 to $1,040.00 and gave the stock an “overweight” rating in a report on Wednesday, October 1st. Wedbush upped their target price on argenex from $800.00 to $880.00 and gave the stock an “outperform” rating in a report on Monday, October 13th. Wall Street Zen upgraded argenex from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. JPMorgan Chase & Co. upped their price objective on argenex from $775.00 to $830.00 and gave the company an “overweight” rating in a research note on Monday, August 4th. Finally, Truist Financial upped their price objective on argenex from $700.00 to $918.00 and gave the company a “buy” rating in a research note on Monday, September 15th.

argenex Stock Performance

ARGX opened at $834.75 on Friday. argenex has a 52-week low of $510.05 and a 52-week high of $855.46. The firm has a market capitalization of $51.39 billion, a PE ratio of 42.81, a PEG ratio of 0.91 and a beta of 0.46. The business’s 50-day simple moving average is $742.84 and its 200 day simple moving average is $639.72.

argenex (NASDAQ:ARGX) last released its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.84 by $0.90. argenex had a return on equity of 21.06% and a net margin of 40.98%.The business had revenue of $866.79 million for the quarter, compared to analyst estimates of $776.82 million. On average, research analysts forecast that argenex will post 3.13 earnings per share for the current year.

Institutional Trading of argenex

Several institutional investors and hedge funds have recently bought and sold shares of the business. Global Retirement Partners LLC raised its stake in argenex by 42.7% in the third quarter. Global Retirement Partners LLC now owns 107 shares of the company’s stock valued at $79,000 after buying an additional 32 shares during the period. Signaturefd LLC raised its stake in argenex by 4.2% in the third quarter. Signaturefd LLC now owns 1,749 shares of the company’s stock valued at $1,290,000 after buying an additional 70 shares during the period. PDS Planning Inc bought a new stake in argenex in the third quarter valued at approximately $296,000. Financial Consulate Inc. bought a new stake in argenex in the third quarter valued at approximately $75,000. Finally, Mather Group LLC. bought a new stake in argenex in the third quarter valued at approximately $50,000. Institutional investors own 60.32% of the company’s stock.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.